BioHarvest Sciences (NASDAQ:BHST) Earns Buy Rating from Analysts at Maxim Group

Maxim Group began coverage on shares of BioHarvest Sciences (NASDAQ:BHST) in a research note published on Wednesday, Marketbeat reports. The brokerage issued a buy rating and a $12.00 price target on the stock.

Separately, HC Wainwright initiated coverage on BioHarvest Sciences in a report on Friday, December 6th. They issued a “buy” rating and a $14.00 price objective for the company.

BioHarvest Sciences Price Performance

Shares of NASDAQ BHST opened at $6.29 on Wednesday. BioHarvest Sciences has a twelve month low of $6.10 and a twelve month high of $7.70. The firm has a market cap of $103.31 million and a price-to-earnings ratio of -5.04.

BioHarvest Sciences Company Profile

BioHarvest Sciences Inc is a biotech firm. It focused on leveraging its botanical synthesis technology to develop science-based and clinically proven therapeutic solutions, within business verticals nutraceutical health and wellness products such as dietary supplements and development of plant cell-based Active Pharmaceutical Ingredients which focus on specific medical indications.